Efficacy of acitretin in the treatment of reactive neutrophilic dermatoses in adult-onset immunodeficiency due to interferon-gamma autoantibody.
Acitretin
/ administration & dosage
Age of Onset
Autoantibodies
/ blood
Chemical and Drug Induced Liver Injury
/ epidemiology
Dose-Response Relationship, Drug
Female
Humans
Immunologic Deficiency Syndromes
/ blood
Interferon-gamma
/ immunology
Male
Middle Aged
Retrospective Studies
Sweet Syndrome
/ blood
Treatment Outcome
Sweet syndrome
acitretin
adult-onset immunodeficiency
interferon-gamma autoantibody
reactive neutrophilic dermatoses
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
22
11
2019
accepted:
18
02
2020
pubmed:
25
3
2020
medline:
16
3
2021
entrez:
25
3
2020
Statut:
ppublish
Résumé
Reactive neutrophilic dermatoses in adult-onset immunodeficiency due to interferon-γ autoantibody (AOID) are usually associated with concomitant active opportunistic infections. Data focusing on the treatment of these dermatoses with non-immunosuppressive drugs are still lacking. The aim of this study was to assess the efficacy and safety of acitretin treatment of reactive neutrophilic dermatoses in AOID. We conducted a retrospective review of all patients with AOID who had reactive neutrophilic dermatoses and had been treated with acitretin from January 2008 to December 2018. In total, 23 patients had been diagnosed with AOID, with 27 episodes of reactive neutrophilic dermatoses (20 episodes of Sweet syndrome and seven episodes of generalized pustular eruption) and treated with acitretin. The median effective dose of acitretin was 10 mg/day. The mean initial response was 5.6 ± 2.3 days. The rash had almost or completely cleared within 2 weeks in 70.4% of patients. One case had developed a reversible acitretin-induced liver injury with hepatocellular pattern. The median total duration of treatment was 3 months. In conclusion, this study demonstrates the potential role of acitretin as one of the treatments of choice for reactive neutrophilic dermatoses in AOID, attributable to its favorable response and good tolerability.
Identifiants
pubmed: 32207168
doi: 10.1111/1346-8138.15312
pmc: PMC7318687
doi:
Substances chimiques
Autoantibodies
0
IFNG protein, human
0
Interferon-gamma
82115-62-6
Acitretin
LCH760E9T7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
563-568Informations de copyright
© 2020 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Dermatology. 1999;199(2):153-5
pubmed: 10559583
J Dermatolog Treat. 2010 Mar;21(2):114-6
pubmed: 20136575
N Engl J Med. 2012 Aug 23;367(8):725-34
pubmed: 22913682
Int J Dermatol. 2006 Sep;45(9):1131-3
pubmed: 16961541
Acta Derm Venereol. 2018 Aug 29;98(8):742-747
pubmed: 29701234
Orphanet J Rare Dis. 2007 Jul 26;2:34
pubmed: 17655751
Dermatol Ther. 2013 Sep-Oct;26(5):390-9
pubmed: 24099069
Infection. 2011 Feb;39(1):65-71
pubmed: 21128092
J Am Acad Dermatol. 1999 Oct;41(4):584-8
pubmed: 10495381
Medicine (Baltimore). 2016 Jun;95(25):e3927
pubmed: 27336882
Clin Infect Dis. 2005 Aug 1;41(3):291-300
pubmed: 16007523
J Med Assoc Thai. 2013 Dec;96(12):1609-16
pubmed: 24511727
Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):953-64
pubmed: 18624682
Clin Infect Dis. 2007 Aug 15;45(4):421-7
pubmed: 17638188
PLoS One. 2013 Sep 27;8(9):e76371
pubmed: 24086734
J Am Acad Dermatol. 2018 Dec;79(6):987-1006
pubmed: 29653210
Int J Dermatol. 2016 Sep;55(9):1033-9
pubmed: 26967709
Drugs. 1992 Apr;43(4):597-627
pubmed: 1377120
Am J Clin Dermatol. 2009;10(5):301-12
pubmed: 19658442
Dermatology. 2013;226(2):157-66
pubmed: 23652167
Br J Dermatol. 1982 Dec;107(6):681-5
pubmed: 6216907
Ann Pharmacother. 2004 Dec;38(12):2074-7
pubmed: 15494379